Browse by Audience
Skip to content
Papers of the Week
Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies.
Abstract
Galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, has demonstrated a significant reduction in monthly migraine headache days in phase 2 and 3 trials. In these analyses, we aimed to evaluate the safety and tolerability of galcanezumab compared with placebo for prevention of episodic or chronic migraine.